FDA Approves Gilead’s Long-Acting Capsid Inhibitor Lenacapavir For HIV-1

Reuters (12/22, Mahobe, Leo, Mandowara) reports that on Thursday, the FDA approved Gilead Sciences Inc’s lenacapavir (Sunlenca) “therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.” The “injec...